Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2005
08/18/2005WO2005074963A1 Composition for prevention and treatment of diabetic complication
08/18/2005WO2005074962A1 Muscular tension-elevating agent
08/18/2005WO2005074961A1 Body fat-controlling agent
08/18/2005WO2005074923A1 Methods and compositions
08/18/2005WO2005074911A1 Protein kinase c activator
08/18/2005WO2005074909A1 Combination drug
08/18/2005WO2005074907A1 Gene expression controlling agent
08/18/2005WO2005026741A3 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
08/18/2005WO2003004608A3 Drug metabolizing enzymes
08/18/2005US20050183146 Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule
08/18/2005US20050182418 Devices and methods for the restoration of a spinal disc
08/18/2005US20050182276 Process for the synthesis and crystalline form of agomelatine
08/18/2005US20050182135 Enhancement of alcohol metabolism
08/18/2005US20050182103 Substituted 2,3-diphenyl pyridines
08/18/2005US20050182077 8-amino-7-substituted-2,6-dioxo-1,2,3,6-tetrahydro-7H-purines; erectile dysfunction; sexual disorders; psychological disorders; hypotensive agents; restenosis; cardiovascular disorders; antidiabetic agents; vision defects; autoimmune diseases; anticancer agents
08/18/2005US20050182068 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
08/18/2005US20050182057 Aryl N-cyanoguanidines and methods related thereto
08/18/2005US20050182045 Fused ring 4-oxopyrimidine derivative
08/18/2005US20050182042 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
08/18/2005US20050182035 cyclohexane ring is 3,5-dihydroxy-substituted and 2,4-alkylene-bridged; treating metabolic bone disease, cancer, skin disorders, immune system disorders, asthma, hypertension, hypothyroidism, hypocalcemia, female infertility and alopecia
08/18/2005US20050182034 Method of locking 1alpha-OH of vitamin D compounds in axial orientation
08/18/2005US20050182019 Phosphonate compounds
08/18/2005US20050181995 Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof
08/18/2005US20050181991 Use of artemin, a member of the GDNF ligand family
08/18/2005US20050181971 Treatment of type i diabetes mellitus
08/18/2005US20050181501 Anti-TECK antibodies and methods of use therefor
08/18/2005US20050181076 Compositions and methods for treatment of diabetes
08/18/2005US20050181042 Composition for oral or rectal administration
08/18/2005US20050180990 Antidiabetic agent and food
08/18/2005US20050180989 Containing Tricholoma matsutake, in particular Tricholoma matsutake of the FERM BP-7304 strain, and any of mycelia, broths, or fruit bodies (including spores) thereof, as they are, dried products thereof, or extracts thereof; anticholesterol agent
08/18/2005US20050180963 Probiotic propionibacterium
08/18/2005US20050180959 Kinases involved in the regulation of energy homeostasis
08/18/2005DE10215908B4 Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel Acyl-3-carboxy-phenyl-urea derivatives and their use as medicaments
08/18/2005CA2555469A1 Use of relaxin-3 for promoting food intake, increasing body weight gain, increasing fat weight and for others
08/18/2005CA2555316A1 Combined pharmaceutical composition
08/18/2005CA2555308A1 Thiazolylimidazole derivatives and their use as inhibitors of microsomal triglyceride transfer protein
08/18/2005CA2553970A1 Spiro-benzodioxoles and their use as cb1 antagonists
08/18/2005CA2552954A1 Use of an extract of pueraria tuberosa for the treatment of diabetes type 2
08/18/2005CA2552404A1 Methods and compositions for the treatment of lipodystrophy
08/17/2005EP1564219A1 N-terminally monopegylated polypeptides and process for their preparation
08/17/2005EP1564202A1 Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these
08/17/2005EP1563071A2 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof
08/17/2005EP1562958A1 N-sulfonylaminothiazole
08/17/2005EP1562943A1 Fused heterocyclic compounds
08/17/2005EP1562933A2 Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
08/17/2005EP1562925A1 Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
08/17/2005EP1562915A1 Farnesoid x receptor agonists
08/17/2005EP1562898A1 Indole derivatives as somatostatin agonists or antagonists
08/17/2005EP1562623A1 Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein
08/17/2005EP1562617A1 New alpha-glucosidase inhibitors from a natural source
08/17/2005EP1562607A1 Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
08/17/2005EP1562605A2 Compounds for modulation of cholesterol transport
08/17/2005EP1562604A1 Prostaglandin compounds for the treatment of obesity
08/17/2005EP1562595A1 Diaryl ethers as opioid receptor antagonists
08/17/2005EP1562583A1 Atorvastatin calcium form vi or hydrates thereof
08/17/2005EP1562576A1 Enhancement of alcohol metabolism
08/17/2005EP1562574A1 2-oxo-ethanesulfonamide derivates
08/17/2005EP1496889B1 Stabilized ascorbic acid derivatives
08/17/2005EP1463725B1 Process and intermediates for pyridazinone antidiabetic agents
08/17/2005EP1436380B1 Composition comprising a lactobacillus strain and uses thereof
08/17/2005EP1429617A4 Methods for sterilizing preparations of digestive enzymes
08/17/2005EP1411895B1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
08/17/2005EP1343761B1 Piperidine mch antagonists and their use in the treatment of obesity
08/17/2005EP1289951B1 Growth hormone secretagogues
08/17/2005EP1280757B1 New gamma selective retinoids
08/17/2005EP1267642A4 Starch sub-types and lipid metabolism
08/17/2005EP1265893B1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
08/17/2005EP1248643B1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
08/17/2005EP1144385B1 Benzoheterocycles and their use as mek inhibitors
08/17/2005EP1109908B1 Methods for determining compounds for modulating the body weight
08/17/2005EP1087943B1 Therapeutic biaryl derivatives
08/17/2005EP1023445B1 Cadherin derived growth factor and the application thereof
08/17/2005EP1023067B9 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
08/17/2005EP0894085B1 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
08/17/2005EP0835128B1 Use of il-11 to treat inflammation
08/17/2005CN1656178A Oil-soluble pigment compositions
08/17/2005CN1656125A Extraction of unmilled psyllium
08/17/2005CN1656099A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
08/17/2005CN1656097A Xanthine phosphodiesterase V inhibitor polymorphs
08/17/2005CN1656094A 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
08/17/2005CN1656093A 3-substituted quinuclidines and their use
08/17/2005CN1656091A Tetrahydropyran derivatives
08/17/2005CN1656089A Phenyl-thiophene type vitamin D receptor modulators
08/17/2005CN1656078A Aminoindazole derivatives as protein kinase inhibitor
08/17/2005CN1656077A Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
08/17/2005CN1656075A Quinoline derivatives and their use as 5-HT6 ligands
08/17/2005CN1656072A Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
08/17/2005CN1656070A Melanocortin receptor ligands
08/17/2005CN1656065A Ligand as the RAR receptor inhibitor
08/17/2005CN1656057A N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
08/17/2005CN1655820A Pharmaceutical combination of PDE5 inhibitors with ace inhibitors
08/17/2005CN1655819A Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
08/17/2005CN1655814A Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
08/17/2005CN1655810A Composition for treating or preventing hyperuricemia
08/17/2005CN1655809A Compositions and methods for treating and preventing necrosis
08/17/2005CN1655806A Treatment of diseases involving defective gap junctional communication
08/17/2005CN1655805A Chewable compositions containing a gel-forming extract of psyllium
08/17/2005CN1655797A Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone
08/17/2005CN1655792A Combination product of a 1, 4-benzothiepine 1, 1-dioxide compound with at least one other active ingredient and the use of the product
08/17/2005CN1655787A Triple monoamine reuptake inhibitors for the treatment of chronic pain
1 ... 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 ... 1298